Coeptis Therapeutics (NASDAQ:ZSQR) Stock Price Down 6.3% – What’s Next?

Shares of Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) were down 6.3% during mid-day trading on Monday . The company traded as low as $11.67 and last traded at $11.67. 397,179 shares changed hands during mid-day trading, an increase of 106% from the average session volume of 192,465 shares. The stock had previously closed at $12.46.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen cut shares of Coeptis Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

Coeptis Therapeutics Stock Performance

The firm has a market cap of $596.07 million, a price-to-earnings ratio of -4.60 and a beta of -0.22. The firm’s 50 day moving average is $12.37 and its 200-day moving average is $12.74. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.25 and a current ratio of 3.25.

Coeptis Therapeutics (NASDAQ:ZSQR) last posted its earnings results on Thursday, May 14th. The company reported ($0.65) EPS for the quarter. Coeptis Therapeutics had a negative return on equity of 92.29% and a negative net margin of 810.04%.The business had revenue of $0.11 million for the quarter.

Institutional Investors Weigh In On Coeptis Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Steward Partners Investment Advisory LLC grew its holdings in Coeptis Therapeutics by 100.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock valued at $71,000 after purchasing an additional 2,500 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Coeptis Therapeutics by 12.6% in the fourth quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock worth $600,000 after buying an additional 4,721 shares during the last quarter. State Street Corp boosted its holdings in shares of Coeptis Therapeutics by 35.0% during the 4th quarter. State Street Corp now owns 26,830 shares of the company’s stock worth $382,000 after buying an additional 6,962 shares during the period. Yorkville Advisors Global LP acquired a new position in Coeptis Therapeutics in the 3rd quarter valued at $140,000. Finally, Marshall Wace LLP acquired a new position in Coeptis Therapeutics in the 4th quarter valued at $259,000. 13.88% of the stock is currently owned by institutional investors and hedge funds.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.